Phase I and pharmacokinetic study of Brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer

Clinical Cancer Research

Volumn 9, Issue 8, 2003, Pages 2957-2964

  Ten Tije, Albert J ^a   Verweij, Jaap ^a   Sparreboom, Alex ^b   Van der Gaast, Ate ^a   Fowst, Camilla ^c   Fiorentini, Francesco ^c   Tursi, Jennifer ^c   Antonellini, Alessandro ^c   Mantel, Marijke ^a   Hartman, Carla M ^a   Stoter, Gerrit ^d   Planting, Andre S T ^a   De Jonge, Maja J A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Pharmacia Corporation   (Italy)

^d National Cancer Institute ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADOZELESIN; ALKYLATING AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BROSTALLICIN; CARSELEZIN; DEXAMETHASONE; TALLIMUSTINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DNA BINDING; DRUG DOSE REGIMEN; DRUG HALF LIFE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LEUKOPENIA; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AREA UNDER CURVE; DNA-BINDING PROTEINS; FEMALE; GUANIDINES; HUMANS; INFUSIONS, INTRAVENOUS; INTERCALATING AGENTS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MODELS, CHEMICAL; NEOPLASMS; PYRROLES;

EID: 12444268322     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. D'Incalci, M., and Sessa, C. DNA minor groove binding ligands: A new class of anticancer agents. Expert Opin. Investig. Drugs, 6: 875-884, 1997.
2. Cozzi, P. Distannycin derivatives as potential anticancer agents. Drugs, 4: 573-581, 2001.
3. Marchini, S., Broggini, S., Sessa, C., and D'Incalci, M. Development of distamycin-related DNA binding anticancer drugs. Expert Opin. Investig. Drugs, 10: 1703-1714, 2001.
4. Sessa, C., Pagani, O., Zurlo, M. G., de Jong, J., Hofmann, C., Lassus, M., Marrari, P., Strolin Benedetti, M., and Cavalli, F. Phase I study of the novel distamycin derivative tallimustine (FCE 24517). Ann. Oncol., 5: 901-907, 1994.
5. Wolff, I., Bench, K., Beijnen, J. H., Bruntsch, U., Cavalli, F., de Jong, J., Groot, Y., van Tellingen, O., Wanders, J., and Sessa, C. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days. Clin. Cancer Res., 2: 1717-1723, 1996.
6. Fleming, G. F., Ratain, M. J., O'Brien, S. M., Schilsky, R. L., Hoffman, P. C., Richard, J. M., Vogelzang, N. J., Kasunic, D. A., and Earhart, R. H. Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J. Natl. Cancer Inst., 86: 368-372, 1994.
7. Schwartz, G. H., Aylesworth, C., Stephenson, J., Johnson, T., Cambell, E., Hammond, L., Von Hoff, D. D., and Rowinsky, E. K. Phase I trial of bizelesin using a single bolus infusion given every 28 days in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol., 19: 235a, 2000.
8. Geroni, C., Pennella, G., Capolongo, L., Moneta, D., Rossi, R., Farao, M., Marchini, S., and Cozzi, P. Antitumor activity of PNU-166196, a novel DNA minor groove binder selected for clinical development. Proc. Am. Assoc. Cancer. Res., 41: 265, 2000.
9. Ciomei, M., Pastori, W., Cozzi, P., and Geroni, M. C. Induction of apoptosis with a new distamycin. Proc. Am. Assoc. Cancer Res., 40: 1490, 1999.
10. Giusti, A. M., Moneta, D., Geroni, C., and Farao, M. In vivo induction of apotosis with PNU-166196 in human ovarian carcinoma xenografts. Proc. Am. Assoc. Cancer Res., 41: 2706, 2000.
11. Geroni, C., Marchini, S., Galliera, E., and Broggini, M. Efficacy of the novel DNA minor groove binding agent, Brostallicin, against drug-resistant tumor cells. Proc. Am. Assoc. Cancer Res., 720: 146, 2001.
12. Colella, G., Marchini, S., d'Íncalci, M., Brown, R., and Broggini, M. Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. Br. J. Cancer, 80: 338-343, 1999.
13. Geroni, C., Marchini, S., Cozzi, P., Galliera, E., Ragg, E., Colombo, T., Battaglia, R., Howard, M., D'Incalci, M., and Broggini, M. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res., 62: 2332-2336, 2002.
14. Cozzi, P., Beria, I., Caldarelli, M., Capolongo, L., Geroni, C., Mazzini, S., and Ragg, E. Cytotoxic halogenoacrylic derivatives of distamycin A. Bioorg. Med. Chem. Lett., 10: 1269-1272, 2000.
15. Shen, H., Kauvar, L., and Tew, K. D. Importance of glutathione and associated enzymes in drug response. Oncol. Res., 9: 295-302, 1997.
16. Tsuchida, S., and Sato, K. Glutathione transferases and cancer. Crit. Rev. Biochem. Mol. Biol., 27: 337-384, 1992.
17. World Health Organization: WHO Handbook for Reporting Results of Cancer Teatment. (Offset Publication No. 40). Geneva, Switzerland: WHO, 1979.
18. Awada, A., Punt, C. J., Piccart, M. J., Van Tellingen, O., Van Manen, L., Kerger, J., Groot, Y., Wanders, J., Verweij, J., and Wagener, D. J. Phase 1 study of Carzelesin (U-80, 244) given (4-weekly) by intravenous bolus schedule. Br. J. Cancer, 79: 1454-1461, 1999.
19. Delaloge, S., Yovine, A., Taamma, A., Riofrio, M., Brain, E., Raymond, E., Cottu, P., Goldwasser, F., Jimeno, J., Misset, J. L., Marty, M., and Cvitkovic, E. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J. Clin. Oncol., 19: 1248-1255, 2001.
20. PNU-166196A Investigator Brochure, Pharmacia & Upjohn. Document N 9950123, Version 2, 31 July, 2000.
21. Viallet, J., Stewart, D., Sheperd, F., Ayoub, J., Cormier, Y., DiPietro, N., and Steward, W. Tallimustine is inactive in patients with previously treated small cell lung cancer. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Lung Cancer, 15: 367-373, 1996.
22. Weiss, G. R., Poggesi, I., Rocchetti, M., DeMaria, D., Mooneyham, T., Reilly, D., Vitek, L. V., Whaley, F., Patricia, E., Von Hoff, D. D., and O'Dwyer, P. A phase I and pharmacokinetic study of tallimustine [PNU152241 (FCE 24517)] in patients with advanced cancer. Clin. Cancer Res., 4: 53-59, 1998.